NYSEAMERICAN:CRMDCorMedix Stock Price, Forecast & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CorMedix.

CorMedix is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for CorMedix.

CorMedix Inc. (NYSEAMERICAN:CRMD) announced its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.02. The biotechnology company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.15 million. View CorMedix's earnings history.

CorMedix shares reverse split before market open on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of CorMedix stock prior to the reverse split would have 20 shares after the split.

2 Wall Street analysts have issued 12-month target prices for CorMedix's shares. Their forecasts range from $12.00 to $14.00. On average, they anticipate CorMedix's share price to reach $13.00 in the next year. This suggests a possible upside of 182.0% from the stock's current price. View analysts' price targets for CorMedix.

News headlines about CRMD stock have been trending extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CorMedix earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutCorMedix.

Some companies that are related to CorMedix include Biotest (BIO), Neptune Wellness Solutions (NEPT), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), Medicenna Therapeutics (MDNA), ProMetic Life Sciences (PLI), IMV (IMV), Emblem (EMC), Pfenex (PFNX), Exicure (XCUR), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), Novacyt (NCYT) and Theratechnologies (TH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include ZIOPHARM Oncology (ZIOP), Rexahn Pharmaceuticals (REXN), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), Kindred Biosciences (KIN) and Opko Health (OPK).

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

CorMedix's stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (1.74%), Geode Capital Management LLC (1.37%), Nuveen Asset Management LLC (0.72%), Bank of New York Mellon Corp (0.34%), Steward Partners Investment Advisory LLC (0.29%) and Oxford Financial Group Ltd. (0.21%). Company insiders that own CorMedix stock include Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook and Steven W Lefkowitz. View institutional ownership trends for CorMedix.

CRMD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Deutsche Bank AG, JPMorgan Chase & Co., and UBS Group AG. View insider buying and selling activity for CorMedix.

CRMD stock was bought by a variety of institutional investors in the last quarter, including Oxford Financial Group Ltd., Geode Capital Management LLC, Nuveen Asset Management LLC, GSA Capital Partners LLP, Wells Fargo & Company MN, Alliancebernstein L.P., Raymond James & Associates, and State Street Corp. Company insiders that have bought CorMedix stock in the last two years include Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook, and Steven W Lefkowitz. View insider buying and selling activity for CorMedix.

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRMD stock can currently be purchased for approximately $4.61.

CorMedix has a market capitalization of $120.45 million. CorMedix employs 22 workers across the globe.

The official website for CorMedix is www.cormedix.com.

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.